Remember they took a company to 1 Billion!!!28 Nov 2025 11:16
These guys are not here doing the RTO to keep the share price where it is today!! Thy will be looking to create another 1 billion value company!!!
About A2A Pharmaceuticals
A2A Pharmaceuticals is a private, well-funded company that uses proprietary computational systems, including generative AI with its SCULPT™ platform to accelerate the development of novel drug alternatives for life threatening diseases like cancer. This enables a more efficient process than traditional trial and error approaches to drug discovery.
A2A Pharmaceuticals aims to develop therapies to early clinical stages and then spin them out into standalone entities to progress them through clinical development. In 2018 A2A Pharmaceuticals spun out its MLL-Menin program to Biomea Fusion, Inc. ("Biomea Fusion"), a company that completed an IPO on Nasdaq in 2021 raising US$153 million and listing with a market capitalisation of US$464 million. Post-IPO Biomea's market capitalisation reached a peak of over US$1 billion.